Key terms
About GLSI
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GLSI news
Mar 13
6:05am ET
Greenwich LifeSciences extends lock-up of directors and officers
Mar 12
6:05am ET
Greenwich LifeSciences initiates first clinical sites in Europe
Feb 28
6:27am ET
Expanding Horizons: Bullish Buy Rating as Greenwich LifeSciences’s Breast Cancer Trial Goes Pan-European
Feb 27
6:22am ET
Greenwich LifeSciences’ Flamingo-01 Phase 3 trial expanding in Europe
Feb 22
6:09am ET
Greenwich LifeSciences’ Phase 3 trial protocol accepted by European regulators
Feb 20
6:30am ET
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), BioMarin Pharmaceutical (BMRN) and Greenwich LifeSciences (GLSI)
Feb 20
6:14am ET
Greenwich LifeSciences price target lowered to $36 from $38 at H.C. Wainwright
Feb 14
4:24pm ET
Greenwich LifeSciences Reports Progress in Flamingo-01 Trial
Feb 14
6:24am ET
Greenwich LifeSciences provides update on Phase III clinical trial Flamingo-01
No recent press releases are available for GLSI
GLSI Financials
Key terms
Ad Feedback
GLSI Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GLSI Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
